Skip to main content
CING
NASDAQ Life Sciences

Cingulate Inc. Closes $6.5M Private Placement Tranche and Converts $1.85M Debt to Equity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.69
Mkt Cap
$57.336M
52W Low
$3.2
52W High
$7.75
52W Position info
140% above low
Off High info
at 52W high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

CING has more than doubled off its 52-week low of $3.2 on elevated volume (2.4× avg).

Summary

Cingulate Inc. announced the closing of a $6.5 million portion of its previously disclosed private placement and detailed multiple debt-to-equity conversions totaling $1.85 million.


Key Events · Financing and Capital Events · CING

  • Private Placement Tranche Closed

    The company completed a $6.5 million portion of the private placement announced on January 28, 2026, with the remaining $5.5 million expected to close soon.

  • Debt-to-Equity Conversions

    Cingulate issued 361,409 shares of common stock between January 6 and February 5, 2026, converting approximately $1.85 million in debt to equity at varying prices.


Analysis · CING · Life Sciences

This 8-K provides a critical update on Cingulate's ongoing capital raising efforts. The closing of a significant tranche of the private placement, combined with substantial debt-to-equity conversions, injects necessary capital into the company but also results in considerable dilution. This follows a series of recent financing activities, including a $200 million shelf registration and expanded At-The-Market offerings, underscoring the company's continuous need for funding to support its operations. The market's reaction to this dilution, especially with the stock trading near its 52-week high, will be closely watched.

How filings like this one have moved

In the 30 days to Sep 19, 2026, 34.7% of the 1096 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CING was trading at $7.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.3M. The 52-week trading range was $3.20 to $7.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CING - Latest Insights

CING
Aug 13, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $5.14 info
Change: +$0.020 (+0.39%) info
Market Cap: $76.199M info
CING
Aug 13, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.12
Real-time Price: $5.14 info
Change: +$0.020 (+0.39%) info
Market Cap: $76.199M info
CING
Jul 02, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $5.14 info
Change: -$0.7611 (-13%) info
Market Cap: $76.199M info
CING
Jun 16, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.87
Real-time Price: $5.14 info
Change: +$0.274 (+6%) info
Market Cap: $76.199M info
CING
Jun 02, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.79
Real-time Price: $5.14 info
Change: +$1.35 (+36%) info
Market Cap: $76.199M info